CFTR and cancer: While historically having a heterozygous CFTR pathogenic variant (PV) was once thought to be relatively benign, data are emerging that dysfunction of CFTR in either people with CF or carriers of a single CFTR PV may increase risk of cancer and other diseases [12, 13, 14, 15].